Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | USP5 | P45974 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22003261 | 0.81 | HIF1A (0.34) | EGLN1HIF1AALDH1A1TDP1 | |
| SCHEMBL3420726 | 0.72 | EGLN1 (0.54) | EGLN1HIF1AUSP5EGLN2EGLN3 | |
| SCHEMBL24005735 | 0.64 | EGLN1 (0.46) | EGLN1EGLN3 | |
| SCHEMBL24005450 | 0.63 | LIPG (0.39) | EGLN1KDM4E | |
| SCHEMBL2796671 | 0.62 | ALDH1A1 (0.67) | HIF1AUSP5ALDH1A1KDM4EHPGD | |
| SCHEMBL21129642 | 0.61 | HIF1A (0.38) | EGLN1HIF1AEGLN2EGLN3 | |
| SCHEMBL17629502 | 0.60 | EGLN1 (1.00) | EGLN1EGLN2EGLN3 | |
| SCHEMBL21129551 | 0.60 | ENPP2 (0.50) | EGLN1ALDH1A1EGLN2EGLN3 | |
| SCHEMBL833438 | 0.59 | ATM (0.52) | HIF1AKDM4EMAPT | |
| SCHEMBL22003117 | 0.59 | LIPG (0.37) | EGLN1HIF1AALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885HIF1A 4/4885USP5 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.